Yulia Slavina

NeoGenomics unveils high-sensitivity MRD platform for early cancer recurrence detection

NeoGenomics unveils high-sensitivity MRD platform for early cancer recurrence detection
NeoGenomics unveils RaDaR ST

NeoGenomics introduces RaDaR ST, a new technology designed to identify minimal residual disease by detecting tumor DNA well before traditional imaging methods can reveal signs of recurrence.

The highly sensitive MRD platform aims to support oncologists in making earlier, more confident decisions in patient care, potentially improving treatment outcomes. The company positions this innovation as a key advance in precision oncology, signaling a move toward more proactive cancer management.

NeoGenomics’ unveiling of RaDaR ST builds on its ongoing efforts to advance precision oncology, following the debut of platforms such as PanTracer Pro, which simplified molecular testing to enhance patient care. The company’s commitment to innovation is also reflected in its continued focus on emerging scientific frontiers, including recent work on spatial biology and strategies to address immunotherapy resistance presented at major industry events.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.